+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Bladder Cancer: Update Bulletin #2

  • PDF Icon


  • May 2024
  • Region: Global
  • FirstWord Publishing
  • ID: 4521364

This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets.

Business Questions:
  • How do the KOLs perceive the Phase II combination results for BMS’ Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer?
  • Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward?
  • What are experts’ thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer?
  • Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity?
  • If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitor?
  • Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC?
  • Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why?
  • How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent?
  • If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC?
  • What are KOLs’ opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed?